Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays

Journal of Virological Methods

Volumn 79, Issue 2, 1999, Pages 227-235

  Pawlotsky, Jean Michel ^a,b   Martinot Peignoux, Michèle ^c   Poveda, Jean Dominique ^d   Bastie, Anne ^a   Le Breton, Véronique ^c   Darthuy, Françoise ^a   Rémiré, Jocelyne ^a   Erlinger, Serge ^c   Dhumeaux, Daniel ^a,b   Marcellin, Patrick ^c  

^a UNIVERSITÉ PARIS OUEST NANTERRE LA DÉFENSE   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

Branched DNA assays; Genotype; Hepatitis C virus; Viral load

Indexed keywords

INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SEQUENCE; RNA TRANSCRIPTION; VIRUS DETECTION; VIRUS LOAD;

DNA, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

HEPATITIS C VIRUS;

EID: 0032946963     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(99)00024-5     Document Type: Article

References (24)

1. Alter H.J., Sanchez-Pescador R., Urdea M., Wilber J.C., Lagier R.J., Di Bisceglie A.M., Shih J.W., Neuwald P.D. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J. Viral Hepatitis. 2:1995;121-132.
2. Collins M.L., Zayati C., Detmer J.J., Daly B., Kolberg J.A., Cha T.A., Irvine B.D., Urdea M.S. Preparation and characterization of RNA standards for use in branched DNA hybridization assays. Ann. Biochem. 226:1995;120-129.
3. Detmer J., Lagier R., Flynn R., Zayati J., Kolberg J., Collins M., Urdea M., Sanchez-Pescador R. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J. Clin. Microbiol. 34:1996;901-907.
4. Gretch D.R. Diagnostic tests for hepatitis C. Hepatology. 26(Suppl. 1):1997;43S-47S.
5. Gretch D.R., dela Rosa C., Carithers R.L., Willson R.A., Williams B., Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann. Intern. Med. 123:1995;321-329.
6. Hawkins A., Davidson F., Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2 and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay and in-house limiting dilution method. J. Clin. Microbiol. 35:1997;187-192.
7. Jacob S., Baudy D., Jones E., Xu L., Mason A., Regenstein F., Perrillo R.P. Comparison of quantitative HCV RNA assays in chronic hepatitis C. Am. J. Clin. Pathol. 107:1997;362-367.
8. Kolberg, J.A., Sanchez-Pescador, R., Detmer, J., Collins, M., Sheridan, P., Neuwald, P., Wilber, J., Dailey, P., Urdea, M., 1994. Branched DNA (bDNA) quantitation of hepatitis C viral RNA in patient sera. In: Groupe Français d'Etudes Moléculaires des Hépatites (GEMHEP) (Ed.), Hepatitis C Virus: New Diagnostic Tools. John Libbey Eurotext, Paris, pp. 57-70.
9. Lau J.Y.N., Simmonds P., Urdea M.S. Implications of variations of 'conserved' regions of hepatitis C virus genome. Lancet. 346:1995;425-426.
10. Lu R.H., Hwang S.J., Chan C.Y., Chang F.Y., Lee S.D. Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV Monitor system and branched DNA signal amplification assay. J. Clin. Lab. Anal. 12:1998;121-125.
11. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descombes I., LeBreton V., Milotova V., Benhamou J.P., Erlinger S. Pretreatment HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.
12. Martinot-Peignoux M., Boyer N., Pouteau M., Castelnau C., Giuily N., Duchatelle V., Aupérin A., Degott C, Benhamou J.P., Erlinger S., Marcellin P. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 29:1998;214-223.
13. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. for the Hepatitis Interventional Therapy Group, 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339, 1485-1492.
14. Nousbaum, J.B., Pol, S., Nalpas, B., Landais, P., Berthelot, P., Bréchot, C., the Collaborative Study Group, 1995. Hepatitis C virus type 1b (II) infection in France and Italy. Ann. Intern. Med. 122, 161-168.
15. Pawlotsky J.M. Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatology. 26:1997;1-4.
16. Pawlotsky J.M., Gretch D.R. Molecular tools for the treatment of hepatitis C. Schinazi R.F., Sommadossi J.P., Thomas H.C. Therapies for Viral Hepatitis. 1998;103-113 International Medical Press, London.
17. Pawlotsky J.M., Roudot-Thoraval F., Bastie A., Darthuy F., Rémiré J., Métreau J.M., Zafrani E.S., Duval J., Dhumeaux D. Factors affecting treatment responses to interferon-α in chronic hepatitis C. J. Infect. Dis. 174:1996;1-7.
18. Pawlotsky J.M., Lonjon I., Hézode C., Raynard B., Darthuy F., Rémiré J., Soussy C.J., Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology. 27:1998;1700-1702.
19. Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trépo, C., Albrecht, J. for the International Hepatitis Interventional Therapy Group (IHIT), 1998. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426-1432.
20. Smith, D.B., Davidson, F., Yap, P., Brown, H., Kolberg, J., Detmer, J., Urdea, M., Simmonds, P., the International HCV Collaborative Study Group, 1996. Levels of hepatitis C virus in blood donors infected with different viral genotypes. J. Infect. Dis. 173, 727-730.
21. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., van Heuverswyn H., Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J. Gen. Virol. 74:1993;1093-1102.
22. Tong C.Y.W., Hollingsworth R.C., Williams H., Irving W.L., Gilmore I.T. Effect of genotypes on the quantification of hepatitis C virus (HCV) RNA in clinical samples using the Amplicor HCV Monitor test and the Quantiplex HCV RNA 2.0 assay (bDNA). J. Med. Virol. 55:1998;191-196.
23. Urdea, M.S., 1997. Quantification of hepatitis C virus RNA: clinical applications of the branched DNA assay, In: Groupe Français d'Etudes Moléculaires des Hépatites (GEMHEP) (Ed.), Hepatitis C Virus: Genetic Heterogeneity and Viral Load. John Libbey Eurotext, Paris, pp. 73-78.
24. Wolfe, L., Tamatsukuri, S., Sayada, C., Ryff, J.C., 1994. Detection of HCV RNA in serum using a single-tube, single-enzyme PCR in combination with a colorimetric microwell assay, In: Groupe Français d'Etudes Moléculaires des Hépatites (GEMHEP) (Ed.), Hepatitis C Virus: New Diagnostic Tools. John Libbey Eurotext, Paris, pp. 83-94.